Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ENTA
stocks logo

ENTA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
16.00M
-5.65%
-0.535
-49.05%
15.97M
+6.97%
-0.540
-49.06%
16.50M
-9.9%
-0.525
-38.24%
Estimates Revision
The market is revising Downward the revenue expectations for Enanta Pharmaceuticals, Inc. (ENTA) for FY2026, with the revenue forecasts being adjusted by -0.65% over the past three months. During the same period, the stock price has changed by 59.21%.
Revenue Estimates for FY2026
Revise Downward
down Image
-0.65%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-26.72%
In Past 3 Month
Stock Price
Go Up
up Image
+59.21%
In Past 3 Month
Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is 17.00 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is 17.00 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.090
sliders
Low
9.00
Averages
17.00
High
24.00
Current: 14.090
sliders
Low
9.00
Averages
17.00
High
24.00
JPMorgan
Overweight
initiated
$17
2025-11-14
Reason
JPMorgan
Price Target
$17
2025-11-14
initiated
Overweight
Reason
JPMorgan initiated coverage of Enanta with an Overweight rating and $17 price target. The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the positive view. The viral infection has significant unmet need and the study showed faster symptom reduction in the overall population, the analyst tells investors in a research note.
Jefferies
Akash Tewari
Hold
to
Buy
upgrade
$14 -> $20
2025-10-01
Reason
Jefferies
Akash Tewari
Price Target
$14 -> $20
2025-10-01
upgrade
Hold
to
Buy
Reason
Jefferies analyst Akash Tewari upgraded Enanta to Buy from Hold with a price target of $20, up from $14.
Jefferies
Hold
to
Buy
upgrade
$14 -> $20
2025-10-01
Reason
Jefferies
Price Target
$14 -> $20
2025-10-01
upgrade
Hold
to
Buy
Reason
As previously reported, Jefferies upgraded Enanta to Buy from Hold with a price target of $20, up from $14, based on increased confidence that the company's RSV antiviral zalicapavir could become the first outpatient antiviral approved for RSV. While acknowledging that this week's Phase 2b RSV data in high-risk adults missed its primary endpoint, the firm argues that zalicapavir showed a "compelling signal" of about 3-7 days faster symptom resolution in a prespecified subgroup. The firm also thinks Enanta's early-stage oral drugs targeting KIT and STAT6 "could get more interesting over time," the analyst tells investors.
WestPark Capital
NULL -> Buy
initiated
$24
2025-09-02
Reason
WestPark Capital
Price Target
$24
2025-09-02
initiated
NULL -> Buy
Reason
WestPark Capital initiated coverage of Enanta with a Buy rating and $24 price target.
Citizens JMP
Outperform
maintain
$24 -> $25
2025-08-12
Reason
Citizens JMP
Price Target
$24 -> $25
2025-08-12
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Enanta to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals expects cash and continuing Mavyret income to fund operations into fiscal 2028, the analyst tells investors in a research note.
H.C. Wainwright
Brandon Folkes
initiated
$20
2025-07-28
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20
2025-07-28
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta with a Buy rating and $20 price target. The shares offer a favorable risk/reward at current share levels, driven by the company's upcoming clinical catalysts and diversified pipeline in virology and immunology, the analyst tells investors in a research note. The firm likes the stock into the respiratory syncytial virus Phase 2 data readout.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA.O) is -6.12, compared to its 5-year average forward P/E of 0.73. For a more detailed relative valuation and DCF analysis to assess Enanta Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.73
Current PE
-6.12
Overvalued PE
24.37
Undervalued PE
-22.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.85
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.24
Undervalued EV/EBITDA
-31.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.75
Current PS
0.00
Overvalued PS
11.26
Undervalued PS
2.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 137.44% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ENTA News & Events

Events Timeline

(ET)
2025-11-17
16:02:27
Enanta Announces Q4 Earnings Per Share of 87 Cents, Below Consensus Estimate of $1.01
select
2025-09-30 (ET)
2025-09-30
21:17:29
Enanta's 6.5 Million Share Spot Secondary Offering Set at $10.00
select
2025-09-30
16:18:05
Enanta Launches $50M Secondary Offering; Price Set Between $10.00 and $10.50
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15NASDAQ.COM
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook

  • JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.

  • Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.

  • Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.

  • Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.

[object Object]
Preview
4.0
11-14Benzinga
Microsoft Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday

  • Analyst Ratings Overview: Top Wall Street analysts have updated their ratings on several companies, including Microsoft, Enanta Pharmaceuticals, and Polaris Inc.

  • Microsoft Corp Rating: Baird analyst William Power initiated coverage on Microsoft with an Outperform rating and a price target of $600, while shares closed at $503.29.

  • Enanta Pharmaceuticals Rating: JP Morgan analyst Anupam Rama initiated coverage on Enanta Pharmaceuticals with an Overweight rating and a price target of $17, with shares closing at $11.72.

  • Polaris Inc Rating: Loop Capital analyst Brandon Rolle initiated coverage on Polaris with a Hold rating and a price target of $59, while shares closed at $64.82.

[object Object]
Preview
6.0
11-14SeekingAlpha
Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment

  • Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.

  • Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.

  • Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.

  • Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Enanta Pharmaceuticals Inc (ENTA) stock price today?

The current price of ENTA is 14.09 USD — it has decreased -1.05 % in the last trading day.

arrow icon

What is Enanta Pharmaceuticals Inc (ENTA)'s business?

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

arrow icon

What is the price predicton of ENTA Stock?

Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is 17.00 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Enanta Pharmaceuticals Inc (ENTA)'s revenue for the last quarter?

Enanta Pharmaceuticals Inc revenue for the last quarter amounts to 15.13M USD, increased 3.55 % YoY.

arrow icon

What is Enanta Pharmaceuticals Inc (ENTA)'s earnings per share (EPS) for the last quarter?

Enanta Pharmaceuticals Inc. EPS for the last quarter amounts to -0.87 USD, decreased -36.03 % YoY.

arrow icon

What changes have occurred in the market's expectations for Enanta Pharmaceuticals Inc (ENTA)'s fundamentals?

The market is revising Downward the revenue expectations for Enanta Pharmaceuticals, Inc. (ENTA) for FY2026, with the revenue forecasts being adjusted by -0.65% over the past three months. During the same period, the stock price has changed by 59.21%.
arrow icon

How many employees does Enanta Pharmaceuticals Inc (ENTA). have?

Enanta Pharmaceuticals Inc (ENTA) has 120 emplpoyees as of December 05 2025.

arrow icon

What is Enanta Pharmaceuticals Inc (ENTA) market cap?

Today ENTA has the market capitalization of 406.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free